I have a 7-year-old intact male Boxer presenting with a 2...

Hello there. Thanks for reaching out about this Boxer. A 7-year-old intact male Boxer with a Grade II subcutaneous MCT on the stifle definitely warrants a thorough plan. You're right to be thinking proactively about margins and adjunctive therapies, especially with the breed predisposition and challenging location.

Here's my approach and recommendations:

Confirmation & Comprehensive Staging

First, confirming the Grade II diagnosis via FNA is a good start. However, complete staging is critical for all mast cell tumors, especially a Grade II, before proceeding with definitive surgery. Even with clear thoracic radiographs and no palpable lymphadenopathy, we need more information:

Regional Lymph Node Aspirate: You mentioned no palpable lymphadenopathy, but I would strongly recommend aspirating the regional lymph node (popliteal in this case) regardless. Metastasis to regional lymph nodes can occur even if they are not enlarged. This is a crucial prognostic factor.

Abdominal Ultrasound: This is essential to rule out visceral metastasis (e.g., spleen, liver, mesenteric lymph nodes), which can occur with Grade II MCTs, particularly in Boxers.

Buffy Coat Smear: While less sensitive, it's a quick, inexpensive check for circulating mast cells, especially in higher-grade or metastatic disease.

Baseline Bloodwork & Urinalysis: A CBC, chemistry panel, and UA are important to assess overall health and rule out paraneoplastic effects or concurrent disease.

Ideal Surgical Excision

For a subcutaneous MCT, the ideal surgical margins are 2-3 cm lateral and one fascial plane deep. Given the 2cm size of the mass, a 2-3cm margin would result in a 6-8cm diameter excision, which can be challenging on the stifle.

If a board-certified surgeon is not performing the procedure, I would advise very careful planning, possibly including pre-operative imaging (e.g., MRI) to assess the tumor's depth and relationship to vital structures, helping to guide the most aggressive safe excision.

Adjuvant Therapy Considerations (If Margins are Narrow or Incomplete)

Should the margins be narrow or incomplete, we have several strong adjunctive therapy options. My preference for a Grade II MCT on a limb with incomplete margins would typically be radiation therapy or toceranib (Palladia).

Radiation Therapy: For incompletely excised MCTs, especially on distal limbs where achieving wide margins is difficult, definitive radiation therapy to the surgical bed is often the most effective local control. This can achieve excellent outcomes, often comparable to complete excision. This would involve daily treatments for 3-4 weeks under anesthesia.

Toceranib (Palladia): This is a tyrosine kinase inhibitor that targets c-KIT, a receptor commonly mutated in MCTs.

* c-KIT Mutation Testing: I would strongly recommend sending a sample of the tumor (either from the biopsy or excised tissue) for c-KIT mutation analysis. Tumors with activating c-KIT mutations are more likely to respond to toceranib.
* Protocol: If we proceed with toceranib, the typical dose is 2.5-2.75 mg/kg PO every other day.
* Monitoring: We would monitor for gastrointestinal side effects (vomiting, diarrhea), proteinuria (via UPC), neutropenia, and hepatotoxicity. Dose reductions are often necessary.
* Indications: Toceranib is a strong consideration for incompletely excised Grade II MCTs, especially if radiation is not feasible or desired, or if there's evidence of regional lymph node metastasis.

Prednisone: While prednisone can be useful for mast cell tumors due to its mast cell lytic effects, it is typically used in conjunction with other chemotherapeutics or for palliative care.

* Protocol: If used, a dose of 2 mg/kg PO daily, then tapered per protocol would be appropriate.
* Role: For a Grade II MCT with narrow or incomplete margins, prednisone alone is generally not considered definitive adjuvant therapy to achieve long-term local control or prevent metastasis. It can be part of a multi-drug protocol (e.g., with lomustine or vinblastine) or to help manage symptoms.
Caution: Remember that starting prednisone before* definitive diagnosis and staging for other cancers (like lymphoma) can complicate things, but for an already diagnosed MCT, it's less of a concern.

Prognosis

A Grade II subcutaneous MCT with complete excision generally carries a good prognosis, with median survival times often in the years. However, with incomplete margins, the local recurrence rate can be high, and the metastatic potential for Grade II tumors, while lower than Grade III, is still present. This is why careful staging and consideration of adjuvant therapy are so important.

Next Steps

My recommendation would be:

Complete the staging: Perform an abdominal ultrasound and aspirate the popliteal lymph node (even if not palpable).

Discuss Surgical Options: Consult with an experienced surgeon to determine if wide (2-3cm lateral, one fascial plane deep) margins are achievable on the stifle. If not, discuss the pros and cons of aggressive local excision followed by adjuvant radiation therapy, versus primary surgical excision followed by systemic therapy like toceranib.

Biopsy Submission: Once excised, ensure the entire mass is submitted for histopathology with clear ink marking of surgical margins. Request Kiupel grading and c-KIT mutation testing if toceranib is a strong consideration.

We want to give this Boxer the best chance for a long, good quality of life. Let's get all the information we can to make an informed decision. Please keep me updated once you have more staging results, and we can refine the plan.